remain overweight rate new price target announc acquisit
otezla cash weve done decent amount work molecul
key differ otezla amgn mainstay inflammatori asset
enbrel think deal make logic sens may quibbl
price observ spoke assum base valuat otezla
outlin herein addit otezla as-i highli accret add signific
posit npv amgn hand think benefit increas time net-net
deal add sum part analysi
otezla logic fit morn announc agreement acquir ww
right celg otezla cash net cash tax benefit
transact expect close end expect maintain
least low double-digit otezla sale growth next five year immedi
non-gaap ep accret think good chanc otezla buyer
maxim valu asset given nice fit exist inflammatori franchis
amgn global footprint
initi opex visibl complet guidanc commun
januari get initi clariti financi compani expect increment
increas sg expens also guid non-gaap
expens increas y/i less half increas expens
relat otezla remaind intern larg oncolog program
stock repurchas continu similar rate last five year
deal move needl meaning layer otezla revenu
respect impli
compound-annual-growth-rate consist amgn revenu growth guidanc
elsewher rais sg expens estim in-lin guidanc
rais non-gaap tax rate increas share repurchas
assumpt bring ep estim prior
estim
respect sum-of-part basi otezla add equiti valu net
cash-per-share impact rais sum-of-part fair valu chang primari
valuat method ep target increas
continu like setup combin today updat recent remov
enbrel patent litig overhang quickli approach updat
inhibitor world lung sept continu like setup
global biopharmaceut compani
ep discount
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
quick back-of-the-envelop math see suggest conserv irr
mirr respect assumpt includ exclus
cog cash around declin time increment cash
sg expens grow fast revenu growth cash tax sum-of-
part basi layer otezla increas equiti valu net
impact net cash-per-share increas fair valu analysi
primari valuat methodolog remain appli multipl ep discount
result today updat ep estim increas
target move remain buyer
page
good sold
product sale
total revenu
sell gener administr
total revenu
statement oper
dollar except per share data
provis incom tax tax benefit
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
page
dollar except per share data
total aimovig revenu
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
